Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.10
-0.10 (-0.47%)
Mar 5, 2026, 2:47 PM CET
13.44%
Market Cap 853.60M
Revenue (ttm) 84.66M
Net Income (ttm) 45.91M
Shares Out 40.26M
EPS (ttm) 1.14
PE Ratio 18.55
Forward PE 5.40
Dividend n/a
Ex-Dividend Date n/a
Volume 13
Average Volume 12,676
Open 21.00
Previous Close 21.20
Day's Range 21.00 - 21.10
52-Week Range 17.80 - 27.80
Beta 0.09
RSI 46.69
Earnings Date Mar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 201
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.